IPM Take
The ADC era is moving through oncology, but cervical cancer must not be treated as an afterthought. The early bulumtatug fuvedotin data are not yet practice-changing, and they should not be oversold. But they point to a bigger issue: women with recurrent or metastatic cervical cancer need access to innovation beyond the familiar sequence of platinum, bevacizumab and immunotherapy.
Executive Summary
Mabwell announced that it presented clinical results for 9MW2821, bulumtatug fuvedotin, a nectin-4-targeting antibody-drug conjugate, at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen. ESMO Daily Reporter described early-phase data in recurrent or metastatic cervical cancer, including a confirmed objective response rate of 32.1%, disease control rate of 81.1% and median overall survival of 19.4 months in 53 evaluable patients from a phase I/II study. ESMO also reported activity in patients previously exposed to immunotherapy and noted that a phase III confirmatory trial is ongoing. This remains early-phase evidence and is not a new standard of care.
Why it matters
- Patients: Recurrent or metastatic cervical cancer still carries major unmet need after available treatment backbones fail.
- Clinicians: ADC sequencing will require clarity on prior therapy, target expression and toxicity.
- Regulators: Confirmatory trials will determine whether early activity becomes an approved option.
- Payers: ADC access will raise familiar questions on eligibility, cost, sequencing and value.
The ADC era has arrived loudly in oncology. Breast cancer, bladder cancer, lung cancer and other tumour types have already felt the impact. Cervical cancer now needs to be part of that conversation, not added later as a footnote.
The bulumtatug fuvedotin data presented around ESMO Gynaecological Cancers Congress are early, but they are worth watching. In recurrent or metastatic cervical cancer, ESMO Daily Reporter highlighted a confirmed response rate of 32.1% and disease control rate of 81.1% in 53 evaluable patients, with median overall survival of 19.4 months. Activity was also reported in patients previously exposed to immunotherapy, a group where treatment options remain limited.
This is exactly where excitement and discipline have to sit together.
The results are promising. They are not definitive. The study is early-phase. Confirmatory evidence is still needed. Questions remain around target expression, sequencing after immunotherapy, use after bevacizumab, toxicity management and whether response translates into durable benefit across broader populations.
But the policy point is already visible. As ADCs move into gynaecological cancers, access systems must prepare for a more complex treatment landscape. That means trial availability, biomarker and target-expression strategies, clinician education, payer readiness and equitable access beyond major academic centres.
Cervical cancer is also an equity disease. In many countries, it reflects gaps in vaccination, screening, early diagnosis and treatment access. Innovation in advanced disease does not replace prevention. But patients already living with recurrent or metastatic cancer still need new options.
For IPM, this is the right balance: celebrate the signal, demand the evidence, and prepare the system. Women’s cancers cannot enter the innovation era through the back door.
